Back to search

Peptide record

TPDB09312

Antibacterial Antifungal Hemolysis Toxicity standard
20 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09312
Antibacterial Antifungal Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia Antifungipept CAFPdb dbAMP HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 20-aa standard natural multi-activity (Antibacterial, Antifungal, Hemolysis, and other sources) peptide sequence curated from AntiBP3, Peptipedia, Antifungipept, and other sources, with an available 3D structural model.
Sequence
AWKVFKRLGIGAVLWVLTWG
Physicochemical Analysis
C115H174N28O22
NDCEQHMPSY
GLWV
2300.82
11.64
3
0
13
+3
-5.84
0.900
131.50
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
16500
717.14
1
Residue Composition
number
2
A
1
R
0
N
0
D
0
C
0
E
0
Q
3
G
0
H
1
I
3
L
2
K
0
M
1
F
0
P
0
S
1
T
3
W
0
Y
3
V
Amino Acid Distribution
A: 2 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 3 H: 0 I: 1 L: 3 K: 2 M: 0 F: 1 P: 0 S: 0 T: 1 W: 3 Y: 0 V: 3
Chemical Descriptors
20
C115H174N28O22
2300.82
11.64
+3
-5.84
0.900
Evidence Records 9 records
Evidence 1 Activity

Activity

0% Hemolysis
Toxicity
0.78 µM
Hemolytic Cytotoxic
0% Hemolysis | 0.78 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 2 Activity

Activity

13% Hemolysis
Toxicity
1.56 µM
Hemolytic Cytotoxic
13% Hemolysis | 1.56 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 3 Activity

Activity

29% Hemolysis
Toxicity
3.125 µM
Hemolytic Cytotoxic
29% Hemolysis | 3.125 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 4 Activity

Activity

30% Hemolysis
Toxicity
6.25 µM
Hemolytic Cytotoxic
30% Hemolysis | 6.25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 5 Activity

Activity

43% Hemolysis
Toxicity
12.5 µM
Hemolytic Cytotoxic
43% Hemolysis | 12.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 6 Activity

Activity

66% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
66% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 7 Activity

Activity

83% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
83% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 8 Activity

Activity

98% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
98% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel analogues with potent antibiotic activity based on the antimicrobial peptide, HP(2-9)-ME(1-12). | Biotechnol Lett | 2004
Evidence 9 Hemolysis

Source & Reference

HemoPI PD_Hemolysis
PD_Hemolysis